Why the Renergen (ASX:RLT) share price is climbing higher today

The Renergen (ASX: RLT) share price is climbing 4.5% higher today after the company announced an innovative transport solution for vaccines.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Renergen Ltd (ASX: RLT) share price is climbing higher today. This comes after the company announced a helium powered transport solution for vaccines. At the time of writing, the Renergen share price is up 4.5% to $1.40. In comparison, the All Ordinaries Index (ASX: XAO) is down 0.7% to 6,923 points.

Renergen is a renewable energy business that invests in early-stage alternative energy projects across Africa and other emerging markets. Its focus is on the commercialisation of its Virginia Gas Project which has reserves of both helium and natural gas.

asx share price rise represented by man holding bunch of balloons soaring through the air

Image source: Getty Images

What's moving the Renergen share price higher?

While the broader market falls, the Renergen share price is on the rise as investors welcome the company's positive update.

According to the release, Renergen has created a new vaccine storage solution which effectively simplifies the process of transferring immunisations.

Named 'Renergen Cryo-Vacc', the device enables a minimum of 100 doses to be transported at temperatures between -70 and -150 Celsius. Encased in aluminium, the Renergen Cryo-Vacc utilises liquid helium which is boiled and released over a period of 30 days, without any power supply. This permits vaccines to be transported over long distances, ensuring the doses aren't comprised by heat.

In addition, Renergen noted that the density of liquid helium is significantly lighter than liquid nitrogen. This makes the device easy to carry with an overall weight of just 20 kilos.

The company has filed for patent rights to the design, and is calling on its partners to adopt the ground-breaking solution.

Renergen has reported that not only does its device offer a cost-effective solution, but also allows vaccines to be delivered to remote areas.

What did management say?

Renergen CEO and managing director Mr Stefano Marani commented on the milestone achievement, saying:

As an emerging helium producer, we are proud to have developed this innovative concept, at a time when the world is seeking solutions on how to overcome the COVID-19 pandemic.

…we are inviting partners with the resources to roll-out large-scale manufacture of the Renergen Cryo-Vacc… Importantly, with the devices in circulation, transportation can be completed in a cost-effective manner, given the relatively small size and weight of the devices. Depending on where the helium is sourced, the operating cost of the device should be under US$0.07 per dose per day for the smallest device.

Renergen share price summary

The Renergen share price has had a bumpy ride over the last year. The company's shares reached as high as $1.72 in February, before falling to 52-week low of 84 cents in March.

Renergen shares have, however, been performing better of late and have increased more than 28% over the last 30 days.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Three brightly coloured objects against a backdrop of blue, indication three winning ASX share prices
Share Gainers

Here are the top 10 ASX 200 shares today

It was a lacklustre session on the ASX this Thursday.

Read more »

a couple consider the advice from a man with documents laid out on a table and the man holding a tablet in his hand.
Financial Shares

3 ASX 200 financial shares to sell: experts

ASX 200 financial shares are down 2.5% over six months and up 2.1% in 2026-to-date.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Broker Notes

What is Morgans saying about Cochlear and Northern Star shares?

Here's what the broker is saying about these big names following their updates.

Read more »

A woman with a mobile phone in her hand looks sceptical with a puzzled expression on her face with an eyebrow raised and pursed lips.
Broker Notes

Buy, hold, sell: NextDC, Hub24, PLS Group shares

The market is pessimistic about the next round of talks between the US and Iran.

Read more »

A team of people giving the thumbs up sign.
Broker Notes

5 ASX 200 shares with renewed buy ratings this week

Brokers have indicated continuing confidence in Cochlear, REA, and several other ASX 200 shares.

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Share Gainers

Why Deep Yellow, Develop Global, Resolute Mining, and Santos shares are pushing higher today

These shares are catching the eye on Thursday. But why?

Read more »

An arrow crashes through the ground as a businessman watches on.
Healthcare Shares

Cochlear stock down 40%: How much has this cost ASX investors?

One day can ruin years of success...

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why Black Cat, Mirvac, Qantas, and Temple & Webster shares are falling today

These shares are having a tough session. But why?

Read more »